Walden P - Search Results

1

Wiguna AP, Walden P. Wiguna AP, et al. Among authors: walden p. Exp Dermatol. 2015 Mar;24(3):209-14. doi: 10.1111/exd.12629. Exp Dermatol. 2015. PMID: 25565012

2

Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients.

Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev T, Sparbier K, Sterry W, Walden P. Trefzer U, et al. Among authors: walden p. Int J Cancer. 2004 Jul 10;110(5):730-40. doi: 10.1002/ijc.20191. Int J Cancer. 2004. PMID: 15146563 Free article. Clinical Trial.

3

Differential arginine methylation of the G-protein pathway suppressor GPS-2 recognized by tumor-specific T cells in melanoma.

Jarmalavicius S, Trefzer U, Walden P. Jarmalavicius S, et al. Among authors: walden p. FASEB J. 2010 Mar;24(3):937-46. doi: 10.1096/fj.09-136283. Epub 2009 Nov 16. FASEB J. 2010. PMID: 19917673

The results show for the first time that GPS-2 is differentially methylated at a site that lacks known methylation motifs and that the methylation state is detected by the immune system.-Jarmalavicius, S., Trefzer, U., Walden, P. Differential arginine methylation of …

The results show for the first time that GPS-2 is differentially methylated at a site that lacks known methylation motifs and that the methy …

4

The future of vaccination as a treatment strategy in dermatological diseases.

Sterry W, Walden P. Sterry W, et al. Among authors: walden p. Clin Exp Dermatol. 2002 Oct;27(7):608-13. doi: 10.1046/j.1365-2230.2002.01181.x. Clin Exp Dermatol. 2002. PMID: 12464158 Review.

5

Topical vaccination with functionalized particles targeting dendritic cells.

Baleeiro RB, Wiesmüller KH, Reiter Y, Baude B, Dähne L, Patzelt A, Lademann J, Barbuto JA, Walden P. Baleeiro RB, et al. Among authors: walden p. J Invest Dermatol. 2013 Aug;133(8):1933-41. doi: 10.1038/jid.2013.79. Epub 2013 Feb 20. J Invest Dermatol. 2013. PMID: 23426134 Free article. Clinical Trial.

6

Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results.

Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, Sparbier K, Sterry W, Walden P. Trefzer U, et al. Among authors: walden p. Vaccine. 2005 Mar 18;23(17-18):2367-73. doi: 10.1016/j.vaccine.2005.01.081. Vaccine. 2005. PMID: 15755630 Clinical Trial.

7

Therapeutic vaccination for the treatment of malignant melanoma.

Walden P. Walden P. Recent Results Cancer Res. 2007;176:219-27. doi: 10.1007/978-3-540-46091-6_19. Recent Results Cancer Res. 2007. PMID: 17607929 Review.

8

A phase I trial with a hybrid cell vaccine in patients with metastatic melanoma.

Trefzer U, Weingart G, Chen Y, Adrian K, Audring H, Winter H, Guo YJ, Sterry W, Walden P. Trefzer U, et al. Among authors: walden p. Adv Exp Med Biol. 1998;451:519-25. doi: 10.1007/978-1-4615-5357-1_80. Adv Exp Med Biol. 1998. PMID: 10026921 Clinical Trial. No abstract available.

9

Direct activation of human dendritic cells by particle-bound but not soluble MHC class II ligand.

Baleeiro RB, Wiesmüller KH, Dähne L, Lademann J, Barbuto JA, Walden P. Baleeiro RB, et al. Among authors: walden p. PLoS One. 2013 May 2;8(5):e63039. doi: 10.1371/journal.pone.0063039. Print 2013. PLoS One. 2013. PMID: 23658796 Free PMC article.

10

Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma.

Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Hofmann MA, et al. Among authors: walden p. J Immunother. 2008 Jun;31(5):520-7. doi: 10.1097/CJI.0b013e318174a4df. J Immunother. 2008. PMID: 18463532 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

273 results

Search Page